LBA10Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC. (23rd October 2018) - Zhou, C; Lu, Y; Kim, S-W; Reungwetwattana, T; Zhou, J; Zhang, Y; He, J; Yang, J-J; Cheng, Y; Lee, S H; Bu, L; Xu, T; et al.